Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and saralasin

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with saralasin in 2 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(saralasin)		Trials
(saralasin)		Recent Studies (post-2010) (saralasin)
9,1561875521,4971316

Protein Interaction Comparison

ProteinTaxonomy1-hexadecyl-2-acetyl-glycero-3-phosphocholine (IC50)saralasin (IC50)
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)0.0017
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)0.0017
Type-1 angiotensin II receptorHomo sapiens (human)0.0006
Type-2 angiotensin II receptorHomo sapiens (human)0.0008

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Braquet, P; Hebert, RL; Lamoureux, C; Plante, GE; Sirois, P1
Baer, PG; Cagen, LM1

Other Studies

2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and saralasin

ArticleYear
Hemodynamic effects of PAF-acether.
    Pharmacological research communications, 1986, Volume: 18 Suppl

    Topics: Angiotensin II; Animals; Blood Pressure; Dogs; Female; Hemodynamics; Indomethacin; Platelet Activating Factor; Renal Circulation; Saralasin; Sodium

1986
Platelet activating factor vasoconstriction of dog kidney. Inhibition by alprazolam.
    Hypertension (Dallas, Tex. : 1979), 1987, Volume: 9, Issue:3

    Topics: Alprazolam; Animals; Blood Pressure; Dogs; Ergolines; Female; Kidney; Male; Meclofenamic Acid; Methysergide; Platelet Activating Factor; Platelet Aggregation; Regional Blood Flow; Saralasin; Vascular Resistance; Vasoconstriction

1987